Search Medical Condition
Please enter condition
Please choose location

Heart Attack (Myocardial Infarction) Clinical Trials

A listing of Heart Attack (Myocardial Infarction) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (63) clinical trials

Improving Door-to-Balloon Time in STEMI

Please see Circulation. 2007;116:67-76

Phase N/A

A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions

E.V.O.L.U.T.I.O.N.: A Randomized Study to Evaluate Safety and Efficacy of the Excel Sirolimus Eluting Stent with a Biodegradable Polymer Versus Sirolimus Eluting Stent with a Non-Biodegradable Polymer in the Treatment of Patients with de novo Coronary Artery Lesions. A prospective, randomized, controlled, parallel two-arm multi-center study, comparing the ExcelTM DES ...


Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study)

Type 2 diabetes mellitus is a well-established risk factor for coronary heart disease and atherosclerotic change in coronary artery. So we designed a prospective randomized multi-center trial named the pioglitazone could reduce the recurrence of myocardial infarction in patients with DM and myocardial infarction(PPAR study) to evaluate whether pioglitazone could ...

Phase N/A

Assessment of an Alpha-Glucosidase Inhibitor to Block Cardiac Events in Patients With Myocardial Infarction and IGT (ABC Study)

Type 2 diabetes mellitus is a well-established risk factor for coronary heart disease and atherosclerotic change in the coronary artery develops subclinically in a state of impaired glucose tolerance (IGT). Recently postprandial hyperglycemia as a feature of impaired glucose tolerance is recognized as a significant risk factor for coronary heart ...

Phase N/A

Cerebral Artery Stenosis Coronary Artery Disease and Arrhythmia

There are many reports about the association of coronary artery disease (CAD) and cerebral artery stenosis (CAS), which had been proved to induce stroke and cognition decline after the revascularization including coronary bypass surgery (CABG) or percutaneous coronary intervention. Perfusion defect on nuclear brain scan is also noted to correlate ...


Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study

Cardiovascular disease is a complex multifactorial and polygenic disorder that is thought to result from an interaction between a person's genetic make up and various environmental factors. Although many studies have revealed that several genetic variants increase the risk of cardiovascular disease, the results of these studies remain controversial. The ...

Phase N/A

Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation

Antiplatelet therapy is indispensable for the prevention of stent thrombosis in patients who underwent coronary artery stenting. Similarly, anticoagulant therapy is essential for the prevention of cardiogenic embolism including cerebral infarction in AF patients. However, the combined antithrombotic therapy has been reported to increase the risk of major bleeding for ...


Cologne Register of Wearable Defibrillator (CRWD)

The wearable cardiac defibrillator (WCD) is an alternative to the implantation of cardioverter defibrillator (ICD) for patients at high risk for sudden cardiac death (mostly bridging therapy). The Cologne register of wearable defibrillator (CRWD) is a prospective register for all patient with an indication of wearable defibrillator.

Phase N/A

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized ...


Risk Stratification in Patients With Preserved Ejection Fraction

1000 asymptomatic post-MI patients>40%, at least 40 days till 3 years post-MI, revascularized or without needing further revascularization (in any case without any evidence of ischemia) will be enrolled. The patients will be divided into two categories: 1. Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit vessels 40% ...

Phase N/A